Lewis Karen 4
4 · Apellis Pharmaceuticals, Inc. · Filed Jun 2, 2023
Insider Transaction Report
Form 4
Lewis Karen
Chief People Officer
Transactions
- Sale
Common Stock
2023-06-01$86.00/sh−5,000$430,000→ 41,504 total - Exercise/Conversion
Common Stock
2023-06-01$34.11/sh+5,000$170,550→ 46,504 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-06-01−5,000→ 106,000 totalExercise: $34.11Exp: 2030-05-03→ Common Stock (5,000 underlying)
Footnotes (3)
- [F1]This is a scheduled exercise and sale from an established 10b5-1 plan.
- [F2]This includes 74 shares from the 4/30/23 ESPP Purchase.
- [F3]This stock option was granted on 5/4/2020 and has a four year vesting period. 25% vest one year from grant date. The remaining 75% vest monthly over the last three years of the four year vesting period.